Drug Safety
HCQ and QTc Prolongation: Dr David Liew
Dr. David Liew reviews abstracts #0431 presented at the ACR 2020 annual meeting - and shares the results of the Twitter poll he conducted asking when prescribing HCQ, is an EKG routinely ordered either before or doing.
k dao KDAO2011
4 years 11 months ago
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
Safety of JAKs: Venous Thromboembolic Risk: Dr. Kevin Winthrop
OHSU rheumatologist Dr. Kevin Winthrop in Portland looks at two posters -- abstracts #0215 and #0229 presented Friday at ACR 2020.
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes
Dr. Sheila Reyes discusses abstract #0205 presented Friday at the 2020 ACR annual meeting.
sheila RHEUMarampa
4 years 11 months ago
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
David Liew drdavidliew
4 years 11 months ago
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
Dr. Dinesh Khanna sclerodermaUM
4 years 11 months ago
Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed
Session Date Monday, November 9
Presentation Time: 12:15 PM - 12:30 PM ET
Methotrexate and Nonalcoholic Fatty Liver Disease: Dr Eric Dein
Dr. Eric Dein discusses the findings of abstract #0181 at the ACR 2020 annual meeting.
Eric Dein ejdein1
4 years 11 months ago
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
k dao KDAO2011
4 years 11 months ago
Dr. L Calabrese excellent review of irAEs and a proposed personalized algorithm for mgmt of irAE #ACR20 @LCalabreseDO @rheumnow
He believes there should be more studies combining TNFi or IL-6 with CPI https://t.co/GbvgXtNJnI
k dao KDAO2011
4 years 11 months ago
Dr. Noha Abdel-wahab on timing for grade 3/4 irAE fastest with the skin after exposure to CPI #ACR20 @rheumnow https://t.co/sc5c6Zn3Uq
Janet Pope Janetbirdope
4 years 11 months ago
#hydroxychloroquine is not a ‘cutie’ drug. E Park et al showed that HCQ does not increase QT interval in RA & SLE patients including if on other meds that may affect QT but known heart disease excluded from study #ACR20 #ACR2020 @RheumNow abstr#432 @CRASCRRheum https://t.co/FGVPknmj5q
Eric Dein ejdein1
4 years 11 months ago
More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1
4 years 11 months ago
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
sheila RHEUMarampa
4 years 11 months ago
MTX & liver fibrosis:
71% pts w/low FIB-4i of<1.45
No correlation bet FIB-4 values & cumulative MTX dose
Cumulative MTX dose not sig. ⬆ in pts with FIB-4i >1.45 @RheumNow #ACR20 Abstr#0205 https://t.co/RmyAz9M5fw
Poster Hall